Understanding Cellectis' Share Capital and Voting Rights
Cellectis is a prominent player in the biotechnology industry focusing on developing innovative treatments. Their commitment to transparency allows shareholders to stay informed about key metrics, especially concerning share capital and voting rights. This information is crucial for investors aiming to make informed decisions.
Market Presence and Key Metrics
Cellectis is listed on the Euronext Growth market, indicating its active engagement in attracting investors and sustaining a competitive edge in the biotech sector. The ISIN code for investors is FR0010425595, ensuring easy identification for trading purposes.
Total Shares and Voting Rights
As of the end of October 2024, Cellectis reported a total of 100,093,873 shares outstanding. Among these, there are 88,569,210 voting rights. This distribution illustrates a robust structure of equity and governance, reflecting the company's commitment to enabling shareholder engagement in decision-making processes.
Company Communications and Contact Information
The leadership team at Cellectis understands the importance of maintaining open lines of communication with its investors and the media. Having staff dedicated to media and investor relations ensures that accurate and timely information is disseminated.
Key Contacts for Media and Investor Relations
Pascalyne Wilson serves as the Director of Communications, available for inquiries at +33 (0)7 76 99 14 33. For investor relations, Arthur Stril, the Interim Chief Financial Officer, can be contacted at +1 (347) 809 5980. Such accessibility fosters a dialogue between the company and its stakeholders, enhancing trust and investor confidence.
Future Growth and Strategic Objectives
Cellectis is dedicated to advancing its research and development efforts, ensuring that it remains at the forefront of biotechnological innovations. The focus on improving treatment options is not just beneficial for the company but also for the wider community that stands to gain from new therapies.
Investor Engagement Strategies
By actively engaging with its shareholders, Cellectis aims to cultivate a favorable environment for investment. Strategies include regular updates, reports, and engagement activities, reinforcing their dedication to corporate governance and shareholder value enhancement.
Frequently Asked Questions
What recent updates has Cellectis shared about their share capital?
Recently, Cellectis reported a total of 100,093,873 shares in the capital, with 88,569,210 voting rights as of October 31, 2024.
How can investors contact Cellectis for more information?
Investors can contact Pascalyne Wilson at +33 (0)7 76 99 14 33 or Arthur Stril at +1 (347) 809 5980 for inquiries.
On which market is Cellectis listed?
Cellectis is listed on the Euronext Growth market, which focuses on promoting smaller companies in the biotech sector.
What is the significance of the voting rights structure at Cellectis?
The voting rights structure allows shareholders to participate in important company decisions, fostering a sense of community and investment engagement.
What future plans does Cellectis have for growth?
Cellectis is focused on enhancing its research and development initiatives to create more innovative treatments that will benefit both patients and investors alike.
